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Abstract
Aims: Advanced biliary tract carcinomas (ABC) are malignancies with limited effective therapies for advanced disease. There is little published evidence of
outcomes of ABC patients participating in phase I clinical trials.
Materials and methods: Patient characteristics, treatment details and outcomes of ABC patients treated at a dedicated phase I unit were captured and analysed
from case and trial records.
Results: In total, 123 ABC patients were included in the study, of which 48 patients participated in 41 different phase I trials; 75 (61%) did not participate due to
rapid disease progression or patient choice. Molecular characterisation of tumours using a targeted panel was conducted in 15 (31%), yielding several potentially
actionable mutations, including BRCA, PIK3CA, FGFR, AKT and PTEN loss. Of the 39 evaluable patients there was one exceptional responder. Eighteen (46%) other
patients achieved stable disease as their best response, with a clinical beneﬁt rate at 4 months of 10%. Treatment was generally well tolerated with grade 3 or 4
adverse events only observed in eight patients (17 %), of which six were drug related and led to trial discontinuation in one (3%), with no toxicity-related deaths.
Conclusion: Carefully selected ABC patients have been found to tolerate experimental phase I clinical trials without excess toxicity. The aggressive nature of this
disease warrants consideration of early referral to a phase I unit. Future work will require comprehensive molecular proﬁling in an attempt to understand the
biology underlying the exceptional responders and to match patients in real-time to targeted therapies.
 2017 The Royal College of Radiologists. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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Biliary cancers are a heterogeneous group of cancers,
with varied deﬁnitions and classiﬁcations. Most commonly,
they include tumours of the gallbladder, extrahepatic ducts,
perihilar and intrahepatic ducts and ampullary cancer.
Large clinical trials involving systemic therapy for biliary
cancer have broad inclusion criteria, including almost all
tumours of biliary tract origin [1]. The standard of care for
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inum and gemcitabine [1], but patients invariably progress,
with a median survival of less than 1 year [2]. There are
currently no standard second-line options [3] and patients
are often referred for participation in clinical trials
involving various novel agents targeting multiple potential
pathways, as well as trials using non-systemic local ther-
apy. Early phase clinical trials investigating these agents are
therefore an important option for patients with ABC, but
there are limited published data on the impact of experi-
mental drug therapies on the safety and outcome of
chemo-refractory ABC to guide recommendations and
policy.
In the era of precision medicine, molecular characteri-
sation of tumours has helped to create more efﬁcient clin-
ical trial design and is considered essential in late phased. This is an open access article under the CC BY-NC-ND license (http://
ients with Advanced Biliary Tract Cancer in a Dedicated Phase I Unit,
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of these patient subgroups must start in early phase trials,
allowing for validation of these results in late phase studies.
Increasingly, phase I units throughout the world have star-
ted to routinely perform molecular characterisation of tu-
mours and use these results to guide trial allocation for
patients [5].
We conducted a retrospective analysis of all patients
with ABC treated in the specialist phase I unit in our insti-
tution. The aim of this study was to describe the rates of
toxicities and treatment-related trial discontinuation in
these patients, as well as to describe the anti-tumour ac-
tivity of these agents. We additionally explored the prog-
nostic role of baseline variables for this group of patients
and report on the results of molecular characterisation
carried out on ABC tumours.Materials and Methods
All consecutive patients with ABC treated within phase I
clinical trials in the Drug Development Unit at the Royal
Marsden National Health Service Foundation Trust, Sutton,
UK fromMarch 2002 to March 2016 were included. Patients
eligible for phase I participationwere18 years old and had
progressing ABC tumours for which approved treatments
were no longer available. Patients were discussed at weekly
trial allocation meetings to identify suitable trials based on
disease characteristics, tumour molecular characterisation
results (if available) and trial slot availability. Patients who
received at least one dose of an experimental agent and
provided written informed consent for participation in
phase I trials as approved by the local Research Ethics
Committee were included in this study.
Clinical data that were prospectively collected for each
clinical trial were collated. These included patient charac-
teristics, tumour characteristics and laboratory results. For
each phase I trial: drug name, class of drug, mechanism,
date starting trial, best response, grade of toxicities and date
of progression were collected.
Toxicity data were collected as originally recorded in the
electronic medical records or the case report forms when
required. Toxicities were graded according to the National
Cancer Institute Common Terminology Criteria (NCI-CTC)
for adverse events. Tumour responses were conﬁrmed by a
radiologist using Response Evaluation Criteria in Solid Tu-
mours (RECIST) guidelines.
Molecular Characterisation
From 2011 onwards, patients treated at the Drug Devel-
opment Unit, Royal Marsden Hospital (RMH) were con-
sented to undergo characterisation of key molecular drivers
in the patients’ archival tumour tissue. Through the years,
various panels of targeted next generation sequencing have
been used, for example, from 2013 to mid-2015, 48 genes
were tested using the TruSeq panel, and from the end of
2015 to currently, 113 genes were tested using the Generead
DNA damage panel. Immunohistochemistry (IHC) for ATMPlease cite this article in press as: Sundar R, et al., Clinical Outcome of Pat
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were also dependent on the types of trial and the bio-
markers being selected for these trials during that period of
time. Of particular note, these panels were not speciﬁcally
designed to identify mutations peculiar to ABC. The results
of these tests, if available, were used tomatch themolecular
aberration identiﬁed to a rationally selected experimental
trial, if available.
Statistical Methods
Descriptive statistics were used to summarise patient
and tumour characteristics. The clinical beneﬁt rate was
calculated as the sum of complete response, partial
response and proportion of patients with stable disease at 4
months. For patients included in more than one trial, data
for progression-free survival (PFS) and overall survival from
the ﬁrst trial therapy were used. Overall survival and PFS
were determined using KaplaneMeier analysis and speci-
ﬁed as median survival. Data are presented as survival plots.
Analysis of the effect of potential prognostic factors on
survival was undertaken using Cox proportional hazard
modelling. Categorisation of numeric variables was based
on their deviation from standard reference values. The RMH
prognostic was calculated from a model previously
described [6]. In brief, the RMH prognostic index uses a
composite score of albumin, lactate dehydrogenase and
number of metastatic sites to predict survival in phase I
trials. Factors identiﬁed in univariate models were used to
construct an adjusted survival model.Results
Patient and Tumour Characteristics
Between March 2002 and March 2016, 123 patients with
ABC were reviewed for the consideration of phase I clinical
trials. Eventually, 48 patients (39% of total) participated in a
trial. Of the 75 patients who were reviewed in the clinic but
did not participate in a phase I trial, 15 (20%) patients were
deemed initially eligible for a study trial, but did not receive
any investigational agent due to rapid interim disease
progression. Five patients had passed screening for a study,
but had deterioration of disease condition and performance
status between screening and cycle 1 day 1 and did not
receive drug. The average time between the ﬁrst visit and
screening was 3 weeks. Among the other ABC patients
reviewed in the unit for the consideration of a phase I study,
the most common reasons not to be considered were
biliary-related disease leading to abnormal liver function
and/or bilirubin that would have qualiﬁed as exclusion
criteria for trials (21%), poor performance status (18%) and
patient’s choice (8%).
In total, 48 patients participated in 41 different phase I
clinical trials. Eight (17%) entered a second phase I study
upon progression on the ﬁrst study. The primary site of the
tumour was the bile duct in 36 (75%); patients had amedian
of two previous lines of systemic chemotherapy (rangeients with Advanced Biliary Tract Cancer in a Dedicated Phase I Unit,
R. Sundar et al. / Clinical Oncology xxx (2017) 1e7 31e6). Fourteen (29%) had a biliary stent in situ at the time of
entering a clinical trial. Twenty-eight (58%) had been
diagnosed with upfront metastatic disease, with most
receiving a platinum-based doublet therapy in the ﬁrst line
(90%). Further details of patient and tumour characteristics
are described in Table 1.
Molecular Characterisation
Fifteen patients (31%) had results of molecular charac-
terisation available from targeted next generation
sequencing panels. The most common mutation detected
was in p53 (n ¼ 5; 33%), with other potentially targetable
mutations being detected in PI3KCA (n ¼ 2), FGFR (n ¼ 2),
ERCC (n¼ 1) and AKT (n¼ 1). PTEN loss was detected by IHC
in two patients. Two patients also had known germline
BRCA mutations prior to enrolling into a clinical trial (one
with BRCA1 and one with BRCA2). Nine patients had ATM
IHC carried out, of which one had complete nuclear loss of
expression. Due to logistical considerations of tissue access
and processing, none of the patients with actionable mu-
tations prospectively received treatment on a trial matched
to these mutations.
Phase I Study Outcomes
Thirty-nine patients (81%) participated in novel single
agent trials, whereas nine (19%) participated in trials
combining novel agents with traditional chemotherapeutic
agents. Novel agents targeted several pathways, with the
most common being PI3K pathway inhibitors (35%),
epigenetic agents (17%), DNA damage repair pathway in-
hibitors (10%) and 10% participated in trials utilisingTable 1
Patient characteristics at baseline
Age at diagnosis - years (range) 55 (33e77)
Gender - n (%)
Female 24 (50%)
Male 24 (50%)
Performance status - n (%)
0 14 (29%)
1 34 (71%)
2 0 (0%)
Primary tumour - n (%)
Bile duct 36 (75%)
Gallbladder 6 (13%)
Ampulla of Vater 6 (13%)
Previous lines of treatment - n (%)
1 18 (38%)
2 24 (50%)
3 6 (12%)
Presence of biliary stent - n (%)
Yes 34 (71%)
No 14 (29%)
Time from diagnosis to metastatic
disease - months (range)
4 (0e21)
Time from metastatic disease to
phase I study - months (range)
12 (2e47)
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phase I trials into which patients were enrolled.
Toxicities of Phase I Trials
Experimental therapies were well tolerated, with most
toxicities being grade 1 or 2 (83%). The most common tox-
icities were fatigue (69%), nausea (50%), transaminitis (33%)
and anaemia (33%). Only 17% of patients experienced a
grade 3 or 4 toxicity, with the most common treatment-
related toxicities being neutropenia (n ¼ 2) and trans-
aminitis (n ¼ 2). Most toxicities occurred within the ﬁrst
month of treatment (75%). Dose reductions due to toxicity
were required in 10%, whereas a further 25% of patients
with toxicity were able to continue dosing with a dose
delay. Two (4%) patients had treatment-related inpatient
admissions and one patient (2%) required cessation of
therapy due to toxicity. There were no treatment-related
deaths. Table 2 summarises the various toxicities experi-
enced by patients.
Efﬁcacy
Of the 39 evaluable patients there was one exceptional
responder who had a partial response that was maintained
for 1.5 years on a PARP inhibitor study. Molecular charac-
terisation of this patient’s archival tumour sample revealed
mutations in an in-frame codon deletion of ERBB2, a
truncated PTEN and a mutation in ERCC3. Eighteen other
patients (46%) achieved stable disease as their best
response. The median PFS was 1.9 months (95% conﬁdence
interval 1.5e2.4) (Figure 2) and the median overall survival
was 5.1 months (95% conﬁdence interval 3.2e6.2)
(Figure 3). The clinical beneﬁt rate at 4 months was 10%
(n ¼ 5).
Prognostic Factors
Cox proportional hazard modelling identiﬁed the
following factors as signiﬁcantly (P < 0.1) associated with
overall survival: performance status, site of primary tumour
(bile duct versus gallbladder or ampullary cancer), number
of metastatic sites (two or more), peritoneal metastases,
albumin, lactate dehydrogenase, RMH score and previous
lines of therapy. In an adjusted model, the site of primary
tumour (bile duct versus gall bladder/ampulla), RMH score
(score of 2 or more versus 0) and number of previous lines
of therapy (two versus one) remained signiﬁcant (P < 0.05).
Table 3 presents the various prognostic factors, their uni-
variate and adjusted hazard ratios, 95% conﬁdence intervals
and signiﬁcance levels.Discussion
Clear conclusions regarding the efﬁcacy of treatment for
ABC have been hindered by the relative rarity of various
individual primary sites (e.g. gallbladder, intrahepatic
cholangiocarcinoma, extrahepatic cholangiocarcinoma),ients with Advanced Biliary Tract Cancer in a Dedicated Phase I Unit,
Fig 1. Various classes of phase I trial into which patients were enrolled for the management of advanced biliary tract carcinomas at the Royal
Marsden Hospital Drug Development Unit.
Table 2
Adverse events on phase I trials
Toxicity All grades - n (%) Grades 3e4 - n (%)
Cutaneous/oral
Mucositis 13 (27%) 1 (2%)
Rash 13 (27%) 1 (2%)
Gastrointestinal
Diarrhoea 13 (27%) 0 (0%)
Nausea/vomiting 24 (50%) 0 (0%)
Transaminitis 16 (33%) 3 (6%)
Haematological
Anaemia 16 (33%) 0 (0%)
Neutropenia 8 (17%) 5 (10%)
Febrile neutropenia 2 (4%) 2 (4%)
Thrombopenia 11 (23%) 1 (2%)
Respiratory
Pneumonitis 0 (0%) 0 (0%)
Neurological
Peripheral neuropathy 1 (2%) 0 (0%)
Miscellaneous
Arrhythmia 2 (4%) 0 (0%)
Anorexia 6 (13%) 0 (0%)
Fatigue 33 (69%) 0 (0%)
Hyperglycaemia 5 (10%) 0 (0%)
Other 22 (46%) 2 (4%)
Fig 2. KaplaneMeier curve of progression-free survival of advanced
biliary tract carcinomas patients on phase I trials. Median
progression-free survival: 1.9 months (95% conﬁdence interval
1.5e2.4).
R. Sundar et al. / Clinical Oncology xxx (2017) 1e74making it difﬁcult to conduct large randomised trials for a
particular group. Moreover, it has been shown that the
molecular proﬁle between these various tumours is
different [7,8]. However, for logistical reasons, most trials
tend to include all the various types into the study, leading
to heterogeneous and inconclusive results. Nevertheless,
several novel therapies are currently undergoing trials
investigating their role in the management of ABC; results
(of deﬁnitive beneﬁt from these agents) are eagerly
awaited [3].Please cite this article in press as: Sundar R, et al., Clinical Outcome of Pat
Clinical Oncology (2017), https://doi.org/10.1016/j.clon.2017.11.011Anatomic tumour factors often play a role in the outcome
of patients with ABC, as biliary obstruction is a common
complication, and deranged liver function is often
encountered. Due to the highly experimental nature of
phase I studies, strict inclusion criteriawith respect to organ
function often render this subgroup of patients ineligible for
all-comer studies. This is reﬂected in our study, with more
than a ﬁfth of the patients being referred having abnormal
liver function and only a third of the patients able to enrol
into a study. Of importance is the 20% of patients who were
allocated a study, suggesting ﬁtness at the point of ﬁrst
consultation, but had a deterioration in condition over a
short period of time (usually less than a month), that led to
eventual exclusion from the study. Given the aggressive
nature of the disease, an early or fast-track referral to aients with Advanced Biliary Tract Cancer in a Dedicated Phase I Unit,
Fig 3. KaplaneMeier curve of overall survival of advanced biliary
tract carcinomas patients on phase I trials. Median overall survival:
5.1 months (95% conﬁdence interval 3.2e6.2).
Table 3
Factors examined in overall survival models
Variable (n ¼ 48) Unadjusted
Hazard ratio
(95% conﬁdence interval)
Age 1.00 (0.97e1.03)
Gender: female 0.88 (0.49e1.58)
ECOG PS 2.88 (1.45e5.70)
Primary site of disease
Gall bladder versus bile duct 1.87 (0.77e4.58)
Ampulla versus bile duct 2.86 (1.17e6.97)
Biliary stent in situ 1.60 (0.83e3.06)
Number of metastatic sites
2 2.46 (1.26e4.84)
3 2.43 (0.96e6.19)
4 12.31 (2.50e60.74)
Hepatic metastasis 1.42 (0.74e2.71)
Distant lymph node metastasis 0.95 (0.52e1.72)
Peritoneal metastasis 1.96 (0.99e3.85)
Lung metastasis 1.12 (0.60e2.11)
Bone metastasis 1.45 (0.51e4.12)
Other metastases 3.03 (1.04e8.88)
Haemoglobin 0.88 (0.70e1.10)
White cell count 1.08 (0.94e1.24)
Neutrophil count 1.08 (0.94e1.25)
Lymphocyte count 0.89 (0.53e1.49)
Platelet count 1.00 (1.00e1.01)
Albumin 0.93 (0.88e0.99)
Alanine transaminase 1.00 (0.99e1.01)
Aspartate transaminase 1.00 (0.99e1.01)
Gamma-glutamyl transpeptidase 1.00 (1.00e1.00)
Alkaline phosphatase 1.00 (1.00e1.00)
Lactate dehydrogenase 1.00 (1.00e1.00)
Bilirubin 1.00 (0.97e1.03)
Calcium 0.64 (0.06e7.41)
RMH score
1 versus 0 1.77 (0.86e3.61)
2 or 3 versus 0 3.85 (1.67e8.86)
Number of lines of previous systemic therapy
2 versus 1 0.55 (0.29e1.04)
ECOG PS, Eastern Cooperative Oncology Group performance status; RM
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trials before the natural course of the disease reaches this
inﬂexion point. It is interesting to note that ABC patients
who did eventually enter a phase I study tolerated treat-
ment well, with toxicity rates similar to other tumour
groups, including the rate of transaminitis and hepato-
toxicity, which would be of particular concern in this
tumour group [9,10]. Drug-induced liver toxicity is a major
concern for drug development and historical experience
suggests that ABC patients are possibly at higher risk
compared with other tumour groups (even with broadly
similar inclusion criteria); for example, the rate of liver
toxicity with sorafenib in biliary tract cancer was 6.5% [11]
compared with <1% in renal cell cancer [12]. The clinical
beneﬁt rate at 4months of 10% is at the lower end of average
for phase I trials [10] and is reﬂective of disease biology. This
is suggested by the multivariate analysis, which also iden-
tiﬁed higher tumour burden (number of metastatic sites
and RMH score) as a poor prognostic factor. Among ABCAdjusted
P value Hazard ratio
(95% conﬁdence interval)
P value
0.997
0.678
0.002 1.05 (0.42e2.63) 0.912
0.165 6.52 (1.78e23.94) 0.005
0.021 4.07 (1.22e13.55) 0.022
0.158
0.009 5.29 (2.02e13.85) 0.001
0.062 0.49 (0.10e2.43) 0.385
0.002 0.87 (0.06e12.22) 0.916
0.287
0.858
0.052 1.16 (0.34e3.95) 0.808
0.715
0.49
0.043 2.97 (0.57e15.46) 0.196
0.268
0.253
0.276
0.662
0.137
0.013 0.92 (0.83e1.02) 0.124
0.819
0.702
0.671
0.487
0.006 1.00 (1.00e1.00) 0.087
0.789
0.724
0.119 1.17 (0.41e3.36) 0.774
0.002 8.28 (1.72e39.90) 0.008
0.066 0.29 (0.11e0.77) 0.012
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with gallbladder and ampullary cancer, consistent with
other studies of ABC [13]. In general, ABC patients enrolled
onto phase I trials in our unit had survival outcomes similar
to other tumour groups such as upper gastrointestinal, lung
and mesothelioma [9,14,15]. The outcomes of ABC patients
enrolled on phase I trials were also similar to several
second-line studies conducted with chemotherapeutic
agents, with a median PFS of 3 months and a median overall
survival of 6 months [16]. These poor results explain the
lack of second-line therapies approved for this tumour
group and underpin the efforts required to identify novel
mechanisms to target this disease through experimental
therapeutics and phase I clinical trials.
Molecular proﬁling of biliary tract cancer has revealed
ﬁve major groups of aberrations, each of which could be
potentially targetable [17]. These include mutations in the
MAPK pathway (such as KRAS and BRAF), cell cycle-related
p53 mutations and ampliﬁcation of CCND1, FGFR-related
fusions, IDH mutations and chromatin-modifying genes
such as ARID1A and BAP1. The results of our molecular
characterisation of ABC patients revealed a similar spec-
trum of mutations. Of note, our next generation sequencing
panels did not include IDHmutations and, hence, these may
have been missed in our cohort. The results from the mo-
lecular characterisation of the exceptional responder to
PARP inhibitor therapy revealed PTEN loss on IHC as well as
ERBB2 and ERCC3mutations on next generation sequencing.
It must be highlighted that the results of the molecular
characterisation of the exceptional responder were not
known at the time of enrolment into the study. PTEN loss
has been shown to respond to PARP inhibition in preclinical
models of other tumour types, such as endometrial cancer
[18], as PTEN is involved in maintaining the stability of the
DNA and loss of PTEN leads to synthetic lethality when
combined with PARP inhibition. Similarly, ERCC is a key
protein in the nucleotide excision repair pathway, and tu-
mours with ERCC defects may also respond to PARP inhi-
bition [19]. This highlights the emerging importance of
molecular characterisation as a means to improving cancer
outcomes and personalised medicine. However, one major
concern with ABC is the access to easily available tumour
tissue for testing, which is evident from our study as well, as
several patients did not have sufﬁcient tumour tissue to
perform molecular characterisation. However, with the
advent of analysis using newer technologies such as cfDNA
and circulating tumour cells, perhaps these problems can be
circumvented in the future [20].
Future trial design for ABC must consider moving away
from grouping the various heterogeneous primary sites
together and focusing on molecularly similar tumours [7].
Our study shows a prognostic difference between bile duct
and gallbladder or ampullary cancer, supporting the need to
study these tumour groups as individual entities. Several
new trial designs are evolving for rare tumour groups,
including basket and umbrella trials, Bayesian designs and n
equals 1 trials [21]. Advances in liquid biopsies and the
development of prognostic and predictive biomarkers will
allow for easier characterisation of tumours that arePlease cite this article in press as: Sundar R, et al., Clinical Outcome of Pat
Clinical Oncology (2017), https://doi.org/10.1016/j.clon.2017.11.011notorious for deﬁciency of tissue samples, even for deﬁni-
tive clinical diagnosis [22].Conclusion
Novel agents are required in themanagement of ABC and
an early referral to a clinical trials unit is suggested.
Although liver dysfunction is a common cause for screen
failure prior to entering a study, carefully selected patients
do not have a higher incidence of hepato-toxicity once
enrolled on to a novel therapeutic trial. Future work will
require more comprehensive molecular proﬁling in an
attempt to understand the biology underlying the excep-
tional response, to identify new treatment options, tomatch
patients in real time to targeted therapies and to design
more innovative trials for these rare tumour groups.Acknowledgement
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